triiodothyronine has been researched along with Carcinoma, Renal Cell in 17 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Carcinoma, Renal Cell: A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Subclinical hypothyroidism was characterized by serum TSH above the upper limit of normal and both total triiodothyronine (T3) and thyroxine (T4) within normal limits." | 7.77 | Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. ( Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B, 2011) |
| " Hypothyroidism was considered present if thyroid-stimulating hormone (TSH) exceeded the upper normal limit (UNL) with normal triiodothyronine (T3) and thyroxine (T4)." | 3.78 | Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? ( Hanovich, E; Hercbergs, AH; Kovel, S; Sella, A, 2012) |
| " Subclinical hypothyroidism was characterized by serum TSH above the upper limit of normal and both total triiodothyronine (T3) and thyroxine (T4) within normal limits." | 3.77 | Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. ( Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B, 2011) |
| " There were no changes in T4 concentrations during chronic administration of rhIL-6." | 2.67 | Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans. ( Bakker, PJ; Endert, E; Romijn, JA; Sauerwein, HP; Stouthard, JM; van der Poll, T; Veenhof, CH, 1994) |
| "Triiodothyronine plays an important role in the regulation of kidney cell growth, differentiation and metabolism." | 1.43 | Triiodothyronine regulates cell growth and survival in renal cell cancer. ( Brzezianska-Lasota, E; Czarnecka, AM; Czarnecka, KH; Lewicki, S; Matak, D; Szczylik, C; Szymanski, L; Zdanowski, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 9 (52.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Popławski, P | 3 |
| Piekiełko-Witkowska, A | 2 |
| Nauman, A | 4 |
| Boguslawska, J | 1 |
| Piekielko-Witkowska, A | 1 |
| Wojcicka, A | 2 |
| Kedzierska, H | 1 |
| Poplawski, P | 1 |
| Pani, F | 1 |
| Atzori, F | 1 |
| Baghino, G | 1 |
| Boi, F | 1 |
| Tanca, L | 1 |
| Ionta, MT | 1 |
| Mariotti, S | 1 |
| Czarnecka, AM | 1 |
| Matak, D | 1 |
| Szymanski, L | 1 |
| Czarnecka, KH | 1 |
| Lewicki, S | 1 |
| Zdanowski, R | 1 |
| Brzezianska-Lasota, E | 1 |
| Szczylik, C | 1 |
| Alexandrescu, DT | 1 |
| Popoveniuc, G | 1 |
| Farzanmehr, H | 1 |
| Dasanu, CA | 1 |
| Dawson, N | 1 |
| Wartofsky, L | 1 |
| Master, A | 2 |
| Bogusławska, J | 1 |
| Tański, Z | 2 |
| Darras, VM | 1 |
| Williams, GR | 1 |
| Riesenbeck, LM | 1 |
| Bierer, S | 1 |
| Hoffmeister, I | 1 |
| Köpke, T | 1 |
| Papavassilis, P | 1 |
| Hertle, L | 1 |
| Thielen, B | 1 |
| Herrmann, E | 1 |
| Rosen, MD | 1 |
| Chan, IH | 1 |
| Privalsky, ML | 1 |
| Kappers, MH | 1 |
| van Esch, JH | 1 |
| Smedts, FM | 1 |
| de Krijger, RR | 1 |
| Eechoute, K | 1 |
| Mathijssen, RH | 1 |
| Sleijfer, S | 1 |
| Leijten, F | 1 |
| Danser, AH | 1 |
| van den Meiracker, AH | 1 |
| Visser, TJ | 1 |
| Sella, A | 1 |
| Hercbergs, AH | 1 |
| Hanovich, E | 1 |
| Kovel, S | 1 |
| Fleck, C | 3 |
| Hilger, R | 1 |
| Jurkutat, S | 1 |
| Karge, E | 2 |
| Merkel, U | 1 |
| Schimske, A | 1 |
| Schubert, J | 3 |
| Sartore-Bianchi, A | 1 |
| Soriani, A | 1 |
| Mattioni, R | 1 |
| Vaglio, A | 1 |
| Buzio, C | 1 |
| Porta, C | 1 |
| Turowska, O | 1 |
| Pietrzak, M | 1 |
| Nygard, M | 1 |
| Bondesson, M | 1 |
| Puzianowska-Kuznicka, M | 1 |
| Stouthard, JM | 1 |
| van der Poll, T | 1 |
| Endert, E | 1 |
| Bakker, PJ | 1 |
| Veenhof, CH | 1 |
| Sauerwein, HP | 1 |
| Romijn, JA | 1 |
| Späth-Schwalbe, E | 1 |
| Schrezenmeier, H | 1 |
| Bornstein, S | 1 |
| Burger, K | 1 |
| Porzsolt, F | 1 |
| Born, J | 1 |
| Kratochwil, E | 1 |
| Winterstein, K | 1 |
| Göckeritz, S | 2 |
| Bachner, B | 1 |
| Strohm, U | 1 |
2 trials available for triiodothyronine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
Effects of acute and chronic interleukin-6 administration on thyroid hormone metabolism in humans.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Interleukin-6; Kidney Neopl | 1994 |
Endocrine effects of recombinant interleukin 6 in man.
Topics: Carcinoma, Renal Cell; Hormones; Humans; Interleukin-6; Kidney Neoplasms; Luteinizing Hormone; Male; | 1996 |
15 other studies available for triiodothyronine and Carcinoma, Renal Cell
| Article | Year |
|---|---|
The significance of TRIP11 and T3 signalling pathway in renal cancer progression and survival of patients.
Topics: Aryl Hydrocarbon Receptor Nuclear Translocator; Carcinoma, Renal Cell; Cell Line, Tumor; Cytoskeleta | 2017 |
Regulatory feedback loop between T3 and microRNAs in renal cancer.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Feedback, Physiological; Gene Expression Regulation, Neopla | 2014 |
Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Topics: Adult; Aged; Antineoplastic Agents; Autoantibodies; Autoimmunity; Carcinoma, Renal Cell; Female; Hum | 2015 |
Triiodothyronine regulates cell growth and survival in renal cell cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell | 2016 |
Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
Topics: Antibodies, Anti-Idiotypic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Renal Cell; Dose- | 2008 |
Untranslated regions of thyroid hormone receptor beta 1 mRNA are impaired in human clear cell renal cell carcinoma.
Topics: 5' Untranslated Regions; Alternative Splicing; Base Sequence; Blotting, Western; Carcinoma, Renal Ce | 2010 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Fem | 2011 |
Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas.
Topics: Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Gene Expression Profiling; Gene Expression Regulat | 2011 |
Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Topics: Aged; Animals; Antineoplastic Agents; Body Weight; Capillaries; Carcinoma, Renal Cell; Female; Gastr | 2011 |
Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans | 2012 |
Ex vivo stimulation of renal transport of the cytostatic drugs methotrexate, cisplatin, topotecan (Hycamtin) and raltitrexed (Tomudex) by dexamethasone, T3 and EGF in intact human and rat kidney tissue and in human renal cell carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Carcinoma, Re | 2002 |
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patients.
Topics: Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; | 2004 |
Overexpression of E2F1 in clear cell renal cell carcinoma: a potential impact of erroneous regulation by thyroid hormone nuclear receptors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; DNA; E2F1 Transcription Factor; Female; Gene | 2007 |
In vitro stimulation of renal tubular p-aminohippurate transport by dexamethasone in rat kidneys and in intact kidney tissue of patients suffering from renal cell carcinoma.
Topics: Aged; Animals; Biological Transport, Active; Carcinoma, Renal Cell; Dexamethasone; Female; Humans; I | 1998 |
Ex vivo stimulation of renal tubular p-aminohippurate transport by dexamethasone and triiodothyronine in human renal cell carcinoma.
Topics: ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Renal Cell; Dexamethasone; Dose- | 2000 |